Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Cancer Cell. 2021 Jan 14;39(4):466–479. doi: 10.1016/j.ccell.2020.12.008

Figure 4. Clinical development trajectories of a selection of pan-essential and highly selective targeted therapy drug candidates.

Figure 4.

Clinical trial information for three pan-essential drug candidates discussed in case studies (A) and three successful targeted therapy agents (B) were obtained from clinicaltrials.gov. Clinical trials of corresponding drug candidates are included for this analysis if they have the status suspended, terminated, completed, or withdrawn, or have published trial results.